Aurora Cannabis einfach TOP !!! (Seite 234)
eröffnet am 28.05.18 17:26:58 von
neuester Beitrag 31.05.24 10:28:28 von
neuester Beitrag 31.05.24 10:28:28 von
Beiträge: 14.384
ID: 1.281.132
ID: 1.281.132
Aufrufe heute: 21
Gesamt: 2.460.842
Gesamt: 2.460.842
Aktive User: 0
ISIN: CA05156X8504 · WKN: A4ZZ0W · Symbol: 21P
5,5950
EUR
+3,04 %
+0,1650 EUR
Letzter Kurs 21:05:39 Tradegate
Neuigkeiten
TitelBeiträge |
---|
31.05.24 · wallstreetONLINE Redaktion |
27.05.24 · Hotstock Investor Anzeige |
26.05.24 · wO Chartvergleich |
24.05.24 · wallstreetONLINE Redaktion |
Werte aus der Branche Pharmaindustrie
Wertpapier | Kurs | Perf. % |
---|---|---|
1,5800 | +54,90 | |
0,7172 | +13,34 | |
233,65 | +11,77 | |
36,00 | +11,46 | |
1,7200 | +10,97 |
Wertpapier | Kurs | Perf. % |
---|---|---|
17,670 | -19,68 | |
0,5150 | -31,33 | |
29,21 | -33,60 | |
2,5400 | -34,54 | |
79,70 | -45,37 |
Beitrag zu dieser Diskussion schreiben
Bin auxh drin...und das zum höchsten Kurs heute...schauen wir mal...mich treibt wie immer die Charttechnik...zu 2 hab ich mich noch nicht getraut, nun schon 😄
Kann auch schnell wieder abwärts gehen. Bin auch knapp unter 2 CAD rein, werd mir aber einen Stopp-Loss setzen.
Weiß auch nicht was heute die Canna-Werte treibt
Weiß auch nicht was heute die Canna-Werte treibt
Wo sind die Aurora Basher?
Mal was positives:
"The back story. Aurora Cannabis (ticker: ACB) stock has fallen nearly 76% in the past year, and 27% so far in 2020. Two analysts lowered their neutral ratings and price targets to $1 last week, noting concerns about the firm's ability to generate cash to pay off debt.
Aurora was down 4.2% to $1.58 on Monday morning while the S&P 500 index was up 0.4%. The ETFMG Alternative Harvest exchanged-traded fund (MJ), viewed as a de facto proxy for the pot industry, was up 2.5%.
One of the company's greenhouses appeared in an online sale listing, though the company clarified it was nonoperational and came with its acquisition of MedReleaf. The company said last month Chief Corporate Officer Cam Battley , one of the more public-facing executives in speaking with media and investors, was leaving the company.
Cantor Fitzergald analyst Pablo Zuanic wrote in a note earlier this month that strategic advisor Nelson Peltz should help the company find a chief executive officer who will bring greater financial discipline.
What's new. Zuanic wrote on Monday that the recent stock decline is a reaction to analyst downgrades and " misperceived matters."
"The CCO departure was good news, in our view; a planned asset sale is being done pretty much at book value; and debt covenants imply positive EBITDA by mid-year," he wrote.
He also argues trends have not worsened, noting conversations with management where they reaffirmed their prior outlook for the December quarter. They're also confident sales will ramp up in the second half of the fiscal year, with help from newly introduced cannabis derivative products like edibles and vapes.
"The CCO departure was good news, in our view; a planned asset sale is being done pretty much at book value; and debt covenants imply positive EBITDA by mid-year," he wrote.
He also argues trends have not worsened, noting conversations with management where they reaffirmed their prior outlook for the December quarter. They're also confident sales will ramp up in the second half of the fiscal year, with help from newly introduced cannabis derivative products like edibles and vapes.
"We would make use of the recent pullback (ACB -30% 30d vs. -10% for the group)," he wrote, referring to Canadian cannabis peers. "The poor liquidity makes the stock sensitive to downgrades (some done despite the absence of new catalysts/news) and misplaced market chatter."
Looking Ahead. Zuanic expects positive Ebitda by the June quarter, and operating expenses as a percentage of sales to start coming down.
His fiscal 2020 sales estimate of 338 million Canadian dollars ( US$259 million ) is well below consensus estimates at C$395 million , and is 32% lower than consensus for fiscal 2021. On the other hand, his adjusted Ebitda estimate is C$ 132 million for fiscal 2021, compared to consensus at C$77 million .
Excluding Canopy Growth (CGC) and Cronos Group (CRON), which have investors in big U.S. firms, Aurora deserves a premium to its average peers, given its improving cash flow picture, Zuanic says. Plus, he thinks a potential consumer packaged goods partner, or a well-known CEO, would drive upside.
Write to Connor Smith at connor.smith@barrons.com
"The back story. Aurora Cannabis (ticker: ACB) stock has fallen nearly 76% in the past year, and 27% so far in 2020. Two analysts lowered their neutral ratings and price targets to $1 last week, noting concerns about the firm's ability to generate cash to pay off debt.
Aurora was down 4.2% to $1.58 on Monday morning while the S&P 500 index was up 0.4%. The ETFMG Alternative Harvest exchanged-traded fund (MJ), viewed as a de facto proxy for the pot industry, was up 2.5%.
One of the company's greenhouses appeared in an online sale listing, though the company clarified it was nonoperational and came with its acquisition of MedReleaf. The company said last month Chief Corporate Officer Cam Battley , one of the more public-facing executives in speaking with media and investors, was leaving the company.
Cantor Fitzergald analyst Pablo Zuanic wrote in a note earlier this month that strategic advisor Nelson Peltz should help the company find a chief executive officer who will bring greater financial discipline.
What's new. Zuanic wrote on Monday that the recent stock decline is a reaction to analyst downgrades and " misperceived matters."
"The CCO departure was good news, in our view; a planned asset sale is being done pretty much at book value; and debt covenants imply positive EBITDA by mid-year," he wrote.
He also argues trends have not worsened, noting conversations with management where they reaffirmed their prior outlook for the December quarter. They're also confident sales will ramp up in the second half of the fiscal year, with help from newly introduced cannabis derivative products like edibles and vapes.
"The CCO departure was good news, in our view; a planned asset sale is being done pretty much at book value; and debt covenants imply positive EBITDA by mid-year," he wrote.
He also argues trends have not worsened, noting conversations with management where they reaffirmed their prior outlook for the December quarter. They're also confident sales will ramp up in the second half of the fiscal year, with help from newly introduced cannabis derivative products like edibles and vapes.
"We would make use of the recent pullback (ACB -30% 30d vs. -10% for the group)," he wrote, referring to Canadian cannabis peers. "The poor liquidity makes the stock sensitive to downgrades (some done despite the absence of new catalysts/news) and misplaced market chatter."
Looking Ahead. Zuanic expects positive Ebitda by the June quarter, and operating expenses as a percentage of sales to start coming down.
His fiscal 2020 sales estimate of 338 million Canadian dollars ( US$259 million ) is well below consensus estimates at C$395 million , and is 32% lower than consensus for fiscal 2021. On the other hand, his adjusted Ebitda estimate is C$ 132 million for fiscal 2021, compared to consensus at C$77 million .
Excluding Canopy Growth (CGC) and Cronos Group (CRON), which have investors in big U.S. firms, Aurora deserves a premium to its average peers, given its improving cash flow picture, Zuanic says. Plus, he thinks a potential consumer packaged goods partner, or a well-known CEO, would drive upside.
Write to Connor Smith at connor.smith@barrons.com
Will nicht wirklich hoch.
Kurzer stop up und wieder down.
Kurzer stop up und wieder down.
den Anleger reichen aber nach wie vor unverbindliche Schrotftmeldungen um weiter überteuerte Cannawerte zu kaufen.
Canopy, Tilray, Hexo, Cronos, steigen wegen der Meldung über Gespräche und Vorhaben zu cannabis infused beverage und sehen im Rückgang des Bierkonsums in Kanada ein "Zeichen".und Bestätigung. Der Bierkonsum geht bei uns auch seit Jahren zurück, ganz ohne Cannabis.
Wie klein der Markt ist, wird natürlich verschhwiegen, denn in den legalisierten US-Staaten machen die cannabis-beverage nur knappe 2% der Cannabisumsätze aus.
https://www.thecannabisinvestor.ca/have-no-beer-legal-weed-i…
Canopy, Tilray, Hexo, Cronos, steigen wegen der Meldung über Gespräche und Vorhaben zu cannabis infused beverage und sehen im Rückgang des Bierkonsums in Kanada ein "Zeichen".und Bestätigung. Der Bierkonsum geht bei uns auch seit Jahren zurück, ganz ohne Cannabis.
Wie klein der Markt ist, wird natürlich verschhwiegen, denn in den legalisierten US-Staaten machen die cannabis-beverage nur knappe 2% der Cannabisumsätze aus.
https://www.thecannabisinvestor.ca/have-no-beer-legal-weed-i…
Antwort auf Beitrag Nr.: 62.360.069 von Realdeal99 am 13.01.20 16:57:08Also ich bin schon im Plus 😊
Sorry, hier muss ich leider etwas gemein sein....
Zweistellig nach dem Komma vielleicht, davor die 0
Schaut euch doch einmal diese MK an....die hat meiner Meinung mit einer Realität rein gar nichts zu tun
Sorry, dunkelrot heute obwohl die anderen POT einigermaßen laufen ... da gibt es deutlich bessere Alternativen im POT Sektor
Zweistellig nach dem Komma vielleicht, davor die 0
Schaut euch doch einmal diese MK an....die hat meiner Meinung mit einer Realität rein gar nichts zu tun
Sorry, dunkelrot heute obwohl die anderen POT einigermaßen laufen ... da gibt es deutlich bessere Alternativen im POT Sektor
Antwort auf Beitrag Nr.: 62.359.958 von crackz am 13.01.20 16:51:10Ich fürchte, das ist nur Wunschdenken von dir. Cool wäre es schon.
Denke wir sehen bald wieder 2 stellige Kurse.
Wenn es jetzt losrennt wäre es der Hammer 🔨
Wenn es jetzt losrennt wäre es der Hammer 🔨
31.05.24 · wallstreetONLINE Redaktion · Green Thumb Industries |
26.05.24 · wO Chartvergleich · Carl Zeiss Meditec |
24.05.24 · wallstreetONLINE Redaktion · Aurora Cannabis |
04.05.24 · wallstreetONLINE Redaktion · Green Thumb Industries |
Zeit | Titel |
---|---|
24.01.24 |